Furthermore, inhibitors of Rho/MRTF-regulated gene transcription, CCG-222740 and Rho-kinase inhibitor, markedly enhance the sensitivity of NRAS mutant melanoma cells to the MEK inhibitor trametinib. Here, MAP2K7 is linked to melanoma.